Advancing Drug Resistance Research Through Quantitative Modeling and
  Synthetic Biology by Farquhar, K. et al.
PERSPECTIVE ARTICLE 
 
Advancing Drug Resistance Research Through Quantitative Modeling and Synthetic 
Biology 
 
Kevin Farquhar1, Harold Flohr2, and Daniel A. Charlebois2,* 
1Precision for Medicine, Houston, TX, 77054, USA  
2Department of Physics, University of Alberta, Edmonton, AB, T6G-2E1, Canada 
*Corresponding Author: dcharleb@ualberta.ca 
 
Abstract 
 
Antimicrobial resistance is an emerging global health crisis that is undermining advances in 
modern medicine and, if unmitigated, threatens to kill 10 million people per year worldwide by 
2050. Research over the last decade has demonstrated that the differences between genetically 
identical cells in the same environment can lead to drug resistance. Fluctuations in gene 
expression, modulated by gene regulatory networks, can lead to non-genetic heterogeneity that 
results in the fractional killing of microbial populations causing drug therapies to fail; this non-
genetic drug resistance can enhance the probability of acquiring genetic drug resistance 
mutations. Mathematical models of gene networks can elucidate general principles underlying 
drug resistance, predict the evolution of resistance, and guide drug resistance experiments in the 
laboratory. Cells genetically engineered to carry synthetic gene networks regulating drug 
resistance genes allow for controlled, quantitative experiments on the role of non-genetic 
heterogeneity in the development of drug resistance. In this perspective article, we emphasize the 
contributions that mathematical, computational, and synthetic gene network models play in 
advancing our understanding of antimicrobial resistance to discover effective therapies against 
drug-resistant infections. 
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Introduction 
 
Antimicrobial resistance (AMR) is an emerging health crisis that is undermining modern 
medicine (World Health Organization, 2014). AMR arises when bacteria, fungi, viruses or other 
microbes no longer respond to the antimicrobial drugs used to treat them. As of 2016, 700,000 
deaths per year are attributed to AMR (O’Neill and The Review on Antimicrobial Resistance, 
2016). If unmitigated, it is estimated that by 2050, AMR will kill 10 million people per year 
globally and result in a cumulative lost global production cost of 100 trillion USD. Though it has 
been argued that these figures may be over-estimates (de Kraker et al., 2016), there is 
undoubtedly a large and increasing clinical and public health burden associated with AMR. Drug 
resistance during chemotherapy also continues to be the major limiting factor for successfully 
treating patients with cancer (Vasan et al., 2019). In order to mitigate drug resistance, we need to 
establish new quantitative tools to study the drug resistance process, to discover new drugs, and 
to develop novel treatment strategies that extend the “lifespan” of antimicrobial and 
chemotherapy drugs.  
 
It is well established that drug resistance can develop through genetic mutation (Figure 1A) that 
causes a permanent change in a micro-organism’s DNA or through the acquisition of a drug 
resistance gene (e.g., horizontal gene transfer that occurs in bacteria) (Ochman et al., 2000). 
More recently, research has uncovered a new form of non-genetic stress resistance that can arise 
from fluctuations in gene expression in clonal cell populations (Figure 1B) (Fraser and Kærn, 
2009; Geiler-Samerotte et al., 2013; van Boxtel et al., 2017); this, for example, includes the non-
genetic drug resistance associated with the increased expression of genes that encode efflux 
proteins that pump antimicrobial drugs out of pathogenic yeasts such as Candida glabrata (Ben-
Ami et al., 2016) and Cryptococcus neoformans (Mondon et al., 1999). Targeting this 
phenomenon will be important for mitigating AMR, as some non-genetically drug-resistant 
pathogens are not easily detected by standard laboratory tests (Sears and Schwartz, 2017) and 
non-genetic drug resistance may be associated with the failure of antimicrobial therapies (Ben-
Ami et al., 2016) and chemotherapies (Brock et al., 2009). Non-genetic drug resistance can be 
modulated and enhanced by the structure of a gene regulatory network (Charlebois et al., 2014; 
Inde and Dixon, 2018; Camellato et al., 2019). The emerging paradigm is that drug resistance is 
a multi-stage process and that acute, non-genetic drug resistance can facilitate the evolution of 
permanent, genetic drug resistance (Figure 1C) (Brock et al., 2009; Charlebois et al., 2011; Bodi 
et al., 2017; Farquhar et al., 2019). For instance, it is known that mutations in PDR1, a gene that 
regulates PDR5 in the pleiotropic drug resistance (PDR) network in yeast (Figure 2A), can cause 
full resistance to the antifungal drug fluconazole (Ferrari et al., 2009). Though, more research is 
needed to elucidate the interplay between non-genetic and genetic forms of drug resistance.  
 
Mathematical models of drug resistance have been used for over three decades (Lavi et al., 2012); 
many older mathematical studies were based on ABC (ATP-binding cassette) transporters, such 
as the PDR5 gene that is regulated by PDR1 in the PDR network, as the main mechanism of 
resistance. These models are now beginning to include more contemporary knowledge of AMR 
mechanisms and incorporate how drug resistance gene networks function and evolve during 
treatment (Charlebois et al., 2014; Farquhar et al., 2019). Mathematical models have the potential 
to predict the effectiveness of various treatment strategies, such as using combination drug 
therapies to overcome AMR (Baym et al., 2016), and can guide laboratory experiments by 
identifying experimental targets and by narrowing down the immense number of ways that 
antimicrobial drugs can be applied. Additionally, these models can elucidate mechanisms 
underlying the development of AMR (e.g., Farquhar et al., 2019) and predict AMR from 
experimental data (Arepyeva et al., 2017).  
 
Synthetic biology is rapidly becoming part of the solution to many of our needs in medicine, 
agriculture, and energy production (El Karoui et al., 2019). A particularly promising application 
is to genetically engineer micro-organisms to carry synthetic gene networks to study AMR in a 
more quantitative, controlled, and efficient manner than has been possible using traditional 
(“natural” or non-genetically modified) model micro-organisms (González et al., 2015). At 
present, it is extremely challenging to develop and experimentally validate mathematical models 
using pathogens, where drug resistance genes have evolved to be highly connected to the host 
genome; for instance, the expression of MDR1/p-glycoprotein (responsible for multiple drug 
resistance (MDR) of tumours to chemotherapy; Gottesman et al., 2002) is regulated by a 
multitude of factors, making it difficult to quantitatively study how non-genetic mechanisms may 
contribute to AMR and drug resistance in cancer (Camellato et al., 2019). Furthermore, unlike 
synthetic drug resistance networks, native resistance networks are still not known completely. 
The design of synthetic gene networks is a model-guided process (Sakurai and Hori, 2017) and 
these networks are constructed to mimic natural drug resistance networks using techniques from 
genetic engineering (Cameron et al., 2014; Bartley et al., 2017). 
  
Mathematical Modeling of Non-Genetic Antimicrobial Resistance 
 
Modeling Non-Genetic Gene Expression Heterogeneity in Drug Resistance  
 
Early work on non-genetic drug resistance focused on the amplitude of fluctuations or “noise” in 
the expression of drug resistance genes. Models predicted that low gene expression noise would 
be beneficial under low drug concentrations and that high gene expression noise would be 
beneficial under high drug concentrations (Figure 1B, inset) (Blake et al., 2006; Zhuravel et al., 
2009); these predictions were confirmed experimentally in the same studies. Subsequently, a 
more general theoretical framework was developed that incorporated the frequency of gene 
expression noise, as well as the amplitude (Charlebois et al., 2011). Importantly, using this 
quantitative framework it was hypothesized that drug resistance can develop independently of 
mutation, provided that the fluctuation timescales are sufficiently long. Cell population models 
(Arino and Kimmel, 1993; Henson, 2003; Charlebois and Balázsi, 2019) have also been used to 
incorporate the multi-scale nature of AMR. For instance, a stochastic model of gene expression 
was combined with a population simulation algorithm to computationally investigate the 
evolution of gene expression noise (Charlebois, 2015).  
 
Modeling Drug Resistance Networks in Microbes and Mammalian Cells 
 
Mathematical models have been used to investigate the effect gene network structures or motifs 
have on AMR. For instance, it was shown computationally that gene network motifs can enhance 
drug resistance by modulating non-genetic gene expression variability within a cell population 
(Charlebois et al., 2014). Charlebois et al. showed that feedforward and positive feedback loops, 
the same network motifs that have been found to be imbedded in some gene networks regulating 
AMR in pathogenic yeast (Kolaczkowski et al., 1998) and human cancer cells (Misra et al., 
2005), enhance drug resistance in silico. This new understanding of how gene network structure 
regulates AMR opens up new lines of research and identifies new potential therapeutic targets 
(e.g., targeting regulator genes in the network, rather than the drug resistance genes they control) 
against drug-resistant pathogens and cancers to be investigated experimentally. 
 
Mathematical modeling and computer simulations have been used to predict how drug efflux 
pump proteins affect gene network function and fitness in prokaryotic and eukaryotic organisms. 
In Langevin et al. it was found experimentally that the cellular fitness benefit of AcrAB-TolC, a 
well-known multi-drug resistance pump in E. coli, depended on the rate of stress induction; fits 
to data allowed the fitness benefit that the pumps conferred under different stress induction rates 
to be accurately predicted by mathematical models (Langevin et al., 2018). In another study, it 
was predicted that incorporating negative feedback via drug efflux pumps into synthetic gene 
networks can increase the response of the gene network at low antibiotic inducer concentrations 
(Diao et al., 2016). This prediction was confirmed experimentally in the same study using 
synthetic gene networks in S. cerevisiae and was found to be the result of reduced regulator gene 
expression. 
 
In Farquhar et al., the authors developed a stochastic population dynamics model to infer 
mechanisms for drug resistance in mammalian cells (Farquhar et al., 2019). The stochastic 
population model predicted that gene network motifs facilitate the development of acute drug 
resistance and that non- or slow-growing subpopulations of “persister-like” cells (see Brauner et 
al., 2016, Rosenberg et al., 2018, and Berman and Krysan, 2020 for the distinction between 
“tolerance”, “heteroresistance” or “persistence”, and “resistance”) that do not succumb are 
critical reservoirs for the development of fast growing, heritably drug-resistant mutants enabling 
longer-term drug resistance. This study compliments previous work in bacteria that demonstrated 
that antibiotic tolerant non- or slow-growing mutant cells precede the developed genetic drug 
resistance during intermittent antibiotic exposure (Levin-Reisman et al., 2017). The persistence 
phenotype (e.g., Kussell et al., 2005) and stochastic phenotype switching (e.g., Acar et al., 2008) 
have also been investigated in mathematical models and experiments on genetically engineered 
micro-organisms and found to affect fitness in fluctuating environments. 
 
Ultimately, mathematical and computation models of AMR must be validated by performing 
quantitative drug resistance experiments; genetically engineered cells that harbor synthetic gene 
networks controlling the expression of drug resistance genes is proving to be an effective 
experimental model system.  
 
Synthetic Drug Resistance Gene Networks & Antimicrobial Resistance Experiments 
 
Genetic engineering techniques are used to synthetize and combine DNA to build synthetic gene 
networks or “circuits” (Cameron et al., 2014) that control drug resistance genes. Common 
methods used to engineer synthetic gene networks include recombinant molecular cloning, 
Gibson assembly (Gibson et al., 2009; Santos-Moreno and Schaerli, 2019), and CRISPR-Cas9 
gene editing (Nissim et al., 2014). Cell-to-cell heterogeneity may cause unexpected deviation 
from intended synthetic gene circuit behavior (Beach et al., 2017). However, statistical tools can 
enhance the design process and reliability of synthetic gene networks (Sakurai and Hori, 2017). 
With proper design, synthetic gene networks can be precisely tuned to control gene expression 
mean and noise levels using chemical inducers that do not adversely affect the micro-organisms 
harboring these networks. 
 
Synthetic Antimicrobial Resistance Gene Networks 
 
Synthetic gene networks have been engineered to regulate drug resistance and have been shown 
to serve as well-characterized models of natural stress response modules in evolution 
experiments (González et al., 2015; Bodi et al., 2017; Farquhar et al., 2019; Gouda et al., 2019). 
A synthetic two-gene positive feedback network controlling the Zeocin antibiotic resistance gene 
enables bi-stable gene expression was constructed in S. cerevisiae (Nevozhay et al., 2012). In 
this work, a computational approach based on stochastic cellular movement in gene expression 
space was used to predict cell population fitness of low- and high-expressing subpopulations. 
The authors found an optimum on the fitness landscape that balances the costs and benefits of 
expressing a drug resistance gene in various experimental antibiotic inducer and drug conditions. 
In a subsequent microbial evolution study using the same positive feedback yeast strain, it was 
found that the synthetic gene network was fine-tuned by evolution to modulate the network’s 
noisy response and optimize fitness via specific “intra-circuit” and “extra-circuit” DNA 
mutations (González et al., 2015), which can lead to loss of gene circuit function that can be 
regained in certain conditions under drug selection (Gouda et al., 2019). The study by Gouda et 
al. also suggests that slow growth due to antibiotics may allow cells to access hidden drug-
resistant states prior to genetic changes. Computational models based on fitness and gene 
expression properties have been developed to predict specific aspects of evolutionary dynamics 
(including the speed at which the ancestral genome disappears from the population and the types 
and number of mutant alleles that establish in each experimental condition) in different inducer 
and drug conditions (González et al., 2015). These computational models were validated in the 
same studies by microbial evolution experiments on the genetically engineered positive feedback 
yeast strain (Nevozhay et al., 2012; González et al., 2015; Gouda et al., 2019). 
 
Genetically engineered networks have also been designed to control the expression of genes that 
encode efflux proteins that lead to AMR. Diao et al. used synthetic negative feedback gene 
networks, inducible by the antibiotic doxycycline, to regulate the expression of PDR5 (Diao et 
al., 2016). This study found that the addition of a second layer of negative feedback (resulting 
from pumping doxycycline out of the cell by the PDR5 protein) altered the dose-responses of the 
original gene circuits in a manner that was predictable by mathematical modeling. In another 
study, Camellato et al. engineered a synthetic gene network in yeast to mimic the PDR5 and 
MDR1 networks that underly multi-drug resistance in yeast and human breast cancer cells 
(Figure 2B) (Camellato et al., 2019). In agreement with computational predictions made years 
earlier (Charlebois et al., 2014), the authors found that feedforward and positive feedback 
network motifs enabled rapid, self-sustained activation of gene expression leading to enhanced 
cell survival in the presence of a cytotoxic drug. It has been proposed that activating the 
expression of genes that encode multi-drug resistance efflux pump proteins in the absence of 
antibiotic pressure may allow susceptible bacteria to outcompete resistant bacteria, which 
normally down-regulate the expression of resistance genes in conditions without antibiotics to 
eliminate the associated fitness cost (Wang et al., 2019).  
 
 
Synthetic Drug Resistance Gene Circuits in Mammalian Cells 
 
To experimentally investigate the role of non-genetic heterogeneity in cancer drug resistance, it 
is imperative to precisely control the non-genetic heterogeneity that can drive adaptation to 
chemotherapeutic agents. Synthetic gene circuits integrated in mammalian cells can be designed 
to precisely control gene expression noise for drug resistance genes, while keeping the mean 
expression levels the same (Figure 2F) (Aranda-Díaz et al., 2017; Farquhar et al., 2019). This 
approach allows synthetic gene circuits to separate key biological variables contributing to 
resistance from other confounding variables like mean expression and genetic background. 
 
In Chinese Hamster Ovary (CHO) cells with a Flp-In landing pad (Wirth and Hauser, 2004), 
Farquhar et al. designed, constructed, and integrated into the landing pad a mammalian negative 
feedback (mNF) synthetic gene circuit (Figure 2C) (Farquhar et al., 2019) based on a humanized 
tetracycline repressor (hTetR) regulator gene (Nevozhay et al., 2013); the mNF circuit 
demonstrated doxycycline-inducible expression of a purmoycin drug resistance gene (PuroR) 
with low gene expression noise (Figure 2E). Highlighting the advantages of mathematical 
modeling in synthetic biology, the mNF circuit was originally developed from a derivative gene 
circuit transferred from yeast in a previous study that applied modeling to modify the design of 
the circuit through multiple iterations, leading to increased fold change and minimal gene 
expression noise (Nevozhay et al., 2013). Complementing the low noise drug resistance synthetic 
gene circuit, Farquhar et al. also constructed a mammalian positive feedback (mPF) gene circuit 
(Figure 2D), integrated into the same CHO genomic locus as the mNF circuit, leading to 
doxycycline-inducible expression of PuroR with high levels of gene expression noise (Figure 
2G) (Farquhar et al., 2019). When inducing the two circuits in mammalian CHO cells to express 
the same PuroR mean expression level (Figure 2F) and treating the cells with various 
concentrations of puromycin, the authors found that adaptation to low concentrations of drug was 
favored for the mNF circuit with low gene expression noise. On the other hand, high gene 
expression noise from the mPF circuit facilitated puromycin resistance under high drug 
concentrations. This validated the approach to investigating drug resistance and noise in 
mammalian cells using synthetic gene networks, which were required to decouple noise from 
mean drug resistance gene expression in isogenic cells; this approach could also help to further 
elucidate the role of rare-cell expression and drug-induced reprogramming in mammalian drug 
resistance (Shaffer et al., 2017). 
 
DNA sequencing of the gene circuits after adaptation and monitoring expression and survival 
after temporary removal of drug helped reveal adaptation mechanisms (Farquhar et al., 2019). In 
the mNF circuit, the self-repression from the hTetR regulator tended to break down through 
intra-circuit mutations, leading to higher PuroR expression and irreversible resistance to 
puromycin. In the mPF circuit, no intra-circuit mutations were found despite PuroR expression 
levels remaining elevated above pre-treatment mean expression levels, which was reversible and 
led to re-sensitization to puromycin after inducer removal. By using synthetic gene networks 
containing a drug resistance gene in isogenic mammalian cells, Farquhar et al. addressed a long-
standing question regarding how non-genetic heterogeneity could lead to initial cell survival 
during chemotherapy which then facilitates the development of genetic drug resistance in cancer 
(Brock et al., 2009).  
 
Discussion 
 
A new interdisciplinary field of research is emerging that combines multi-scale quantitative 
models with synthetic biology to rationally design gene networks using engineering principles 
for AMR research. One important goal is to use these models to predict the effects of non-
genetic drug resistance on the evolution of genetic drug resistance. Another important goal is to 
advance pharmaceutical and clinical AMR research by investigating new “resistance proof” 
antimicrobial compounds and novel therapeutic treatment strategies. 
 
Moving forward, a challenge that must be addressed is how to adapt the mathematical models 
and translate the experimental discoveries made using synthetic systems to pathogens with 
complex and highly interconnected gene regulatory networks. More research on pathogenic 
micro-organisms and mammalian cells is needed to elucidate the underpinnings of non-genetic 
resistance at the molecular and single-cell levels. This research will be critical to fully 
understand how non-genetic and genetic mechanisms interact in the development of drug 
resistance, and to discover effective strategies that target acute non-genetic drug resistance to 
alleviate the development of permanent genetic drug resistance in infectious diseases and 
cancers. Several promising approaches include synergistically using noise-enhancing compounds 
to reactivate latent HIV to increase sensitivity to existing antiviral drugs (Dar et al., 2014), using 
combined drug treatment regimens to target non-proliferating M. tuberculosis persisters to 
reduce treatment times (Zhang et al., 2012), eliminating bacterial persisters using engineering 
approaches that target bacterial metabolism (Allison et al., 2011), and the use of epigenetic 
modifiers in combination with targeted therapies to reduce the ability of a cancerous cell to 
switch phenotypes to acquire a drug-resistant state (Salgia and Kulkarni, 2018). 
 
Overall, combining mathematical models and synthetic gene networks is leading to new 
quantitative model systems for drug resistance research, which are desperately needed to 
advance our fundamental understanding of the multi-stage drug resistance process. Ultimately it 
remains to be seen how discoveries made using these quantitative model systems will translate to 
pathogens and cancer. However, the potential of this new area of research to help mitigate the 
socio-economic costs of drug resistance warrants its relentless pursuit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author Contributions 
 
DC conceptualized and supervised the study. KF, HF, and DC all contributed to the literature 
review. HF and DC developed the figures. KF and DC wrote the manuscript.  
 
Funding 
 
Precision provided indirect funding support for this paper by way of employment of KF. No 
additional funding was provided for this paper by Precision or any other entity. 
 
DC is supported in part by funding from the Social Sciences and Humanities Research Council 
(SSHRC) of Canada’s New Frontiers in Research Fund (NFRFE-2019-01208). 
 
Conflict of Interest 
 
The authors declare that the research was conducted in the absence of any commercial or 
financial relationships that could be construed as a potential conflict of interest. 
 
KF was employed by Precision for Medicine. 
 
Acknowledgments 
 
We are grateful to Prof. Gábor Balázsi for helpful comments on the manuscript. We thank Mr. 
Mark Igmen for assisting with the literature review.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References  
 
Acar, M., Mettetal, J. T., and van Oudenaarden, A. (2008). Stochastic switching as a survival 
strategy in fluctuating environments. Nat. Genet. 40: 471-475. doi: 10.1038/ng.110 
 
Allison, K. R., Brynildsen, M. P., and Collins, J. J. (2011). Metabolite-enabled eradication of 
bacterial persisters by aminoglycosides. Nature 473: 216-221. doi:10.1038/nature1006 
 
Aranda-Díaz, A., Mace, K., Zuleta, I., Harrigan, P., and El-Samad, H. (2017). Robust Synthetic 
Circuits for Two-Dimensional Control of Gene Expression in Yeast. ACS Synth. Biol. 6: 545-
554. doi: 10.1021/acssynbio.6b00251.  
 
Arepyeva, M. A., Kolbin, A. S., Sidorenko S. V., Lawson, R., Kurylev, A. A., Balykina, Y. E., et 
al. (2017). A mathematical model for predicting the development of bacterial resistance based on 
the relationship between the level of antimicrobial resistance and the volume of antibiotic 
consumption. J. Glob. Antimicrob Resist. 8: 148-156. doi: 10.1016/j.jgar.2016.11.010 
 
Arino, O., and Kimmel, M. (1993). Comparison of approaches to modeling of cell population 
dynamics. SIAM J. Appl. Math. 53: 1480-1504. doi: 10.1137/0153069  
 
Bartley, B. A., Kim, K., Medley, J. K., and Sauro, H. M. (2017). Synthetic biology: engineering 
living systems from biophysical principles. Biophys. J. 112: 1050‐1058. doi: 
10.1016/j.bpj.2017.02.013 
 
Baym, M., Stone, L. K., and Kishony, R. (2016). Multidrug evolutionary strategies to reverse 
antibiotic resistance. Science 351: aad3292. doi:10.1126/science.aad3292 
 
Beach, R. R., Ricci-Tam, C., Brennan, C. M., Moomau, C. A., Hsu, P-h, Hua, B., et al. (2017).  
Aneuploidy causes non-genetic individuality. Cell 169: 229-242. doi: 10.1016/j.cell.2017.03.021 
 
Ben-Ami, R., Zimmerman, O., Finn, T., Amit, S., Novikov, A., Wertheimer, N., et al. (2016). 
Heteroresistance to Fluconazole is a continuously distributed phenotype among Candida 
glabrata clinical strains associated with in vivo persistence. mBio. 7: e00655-16. 
doi:10.1128/mBio.00655-16 
 
Berman, J., and Krysan, D. J. (2020). Drug resistance and tolerance in fungi. Nat. Rev. 
Microbiol. 18: 319-331. doi: 10.1038/s41579-019-0322-2 
 
Blake, W. J., Balázsi, G., Kohanski, M. A., Isaacs, F. J., Murphy K. F., Kuang, Y., et al. (2006). 
Phenotypic consequences of promoter-mediated transcriptional noise. Mol. Cell. 24: 853-856. 
doi: 10.1016/j.molcel.2006.11.003 
 
Bódi, Z., Farkas, Z., Nevozhay, D., Kalapis, D., Lázár, V., Csörgö, B., et al. (2017). Phenotypic 
heterogeneity promotes adaptive evolution. PLoS Biol. 15: e2000644. doi: 
10.1371/journal.pbio.1002607 
 
Brauner, A., Fridman, O., Gefen, O., and Balaban, N. Q. (2016). Distinguishing between 
resistance, tolerance and persistence to antibiotic treatment. Nature 14: 320-330. doi: 
10.1038/nrmicro.2016.34. 
 
Brock, A., Chang, H., and Huang, S. (2009). Non-genetic heterogeneity – a mutation-
independent driving force for the somatic evolution of tumors. Nat. Rev. Genet. 10: 336-342. doi: 
10.1038/nrg2556 
 
Camellato, B. (2018). Gene regulatory networks are a mechanism for drug resistance. Master’s 
thesis, University of Ottawa. doi: 10.20381/ruor-21371 
 
Camellato, B., Roney, I. J., Azizi, A., Charlebois, D., and Kærn, M. (2019). Engineered gene 
networks enable non-genetic drug resistance and enhances cellular robustness, Eng. Biol. 3: 72-
79. doi: 10.1049/enb.2019.0009 
 
Cameron, D. E., Bashor, C. J., and Collins, J. J. (2014). A brief history of synthetic biology. Nat. 
Rev. Microbiol. 12: 381-390. doi:10.1038/nrmicro3239 
 
Charlebois, D. A., Abdennnur, N., and Kærn, M. (2011). Gene expression noise facilitates 
adaptation and drug resistance independently of mutation. Phys. Rev. Lett. 107: 218101. doi: 
10.1103/PhysRevLett.107.218101 
 
Charlebois, D. A., Balázsi, G., and Kærn, M. (2014). Coherent feedforward transcriptional 
regulatory motifs enhance drug resistance. Phys. Rev. E. 89: 052708. doi: 
10.1103/PhysRevE.89.052708 
 
Charlebois, D. A. (2015). Effect and evolution of gene expression noise on the fitness landscape. 
Phys. Rev. E. 92: 022713. doi: 10.1103/PhysRevE.92.022713 
 
Charlebois, D. A., and Balázsi, G. (2019). Modeling cell population dynamics. In Silico Biol. 13: 
21-39. doi: 10.3233/ISB-180470 
 
Dar, R. D., Hosmane, N. N., Arkin, M. R., Siliciano, R. F., and Weinberger, L. S. (2014). 
Screening for noise in gene expression identifies drug synergies. Science 344: 1392-1396. doi: 
10.1126/science.1250220 
 
de Kraker, M. E. A., Stewardson, A. J., and Harbarth, S. (2016). Will 10 Million People Die a 
Year due to Antimicrobial Resistance by 2050? PLoS Med. 13: e1002184. doi: 
10.1371/journal.pmed.1002184 
 
Diao, J., Charlebois, D. A., Nevozhay, D., Bodi, Z., Csaba, P., and Balázsi, G. (2016). Efflux 
pump control alters synthetic gene circuit function. ACS Synth. Biol. 5: 619–631. doi: 
10.1021/acssynbio.5b00154 
 
El Karoui, M., Hoyos-Flight, M., and Fletcher, L. (2019). Future trends in synthetic biology – a 
report. Front. Bioeng. Biotechnol. 7: 175. doi: 10.3389/fbioe.2019.00175 
Farquhar, K. S., Charlebois, D. A., Szenk, M., Cohen, J., Nevozhay, D., and Balázsi, G. (2019). 
Role of network-mediated stochasticity in mammalian drug resistance. Nat. Commun. 10: 2766. 
doi: 10.1038/s41467-019-10330-w 
 
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., et al. (2009). Gain 
of function mutations in CgPHD1 of Candida glabrata not only mediate antifungal resistance 
but also enhance virulence. PLoS Pathog. 5: e1000268. doi: 10.1371/journal.ppat.1000268 
 
Fraser, D., and Kærn, M. (2009). A chance at survival: gene expression noise and phenotypic 
diversification strategies. Mol. Microbiol. 71: 1333-1340. doi: 10.1111/j.1365-
2958.2009.06605.x 
 
Geiler-Samerotte, K. A., Bauer, C. R., Li, S., Ziv, N., Gresham, D., and Siegal, M. L. (2013). 
The details in the distributions: why and how to study phenotypic variability. Curr. Opin. 
Biotechnol. 24: 752-759. doi: 10.1016/j.copbio.2013.03.010 
 
Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison III, C. A., and Smith, H. O. 
(2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6: 
343-345. doi: 10.1038/NMETH.1318 
 
González, C., Ray, J. C. J., Manhart, M., Adams, R. M., Nevozhay, D., Morozov, A. V., et al. 
(2015). Stress-response balance drives the evolution of a network module and its host genome. 
Mol. Syst. Biol. 11: 827. doi: 10.15252/msb.20156185 
 
Gottesman, M. M., Fojo, T., and Bates, S. E. (2002). Multidrug resistance in cancer: role of 
ATP–dependent transporters. Nat. Rev. Cancer, 2: 48-58. doi: 10.1038/nrc706  
 
Gouda, M. K., Manhart, M., and Balázsi, G. (2019). Evolutionary regain of lost gene circuit 
function. Proc. Natl. Acad. Sci. USA 116: 25162-25171. doi: 10.1073/pnas.1912257116 
 
Henson, M. A. (2003). Dynamic modeling of microbial cell populations. Curr. Opin. Biotech. 
14: 460-467. doi: 10.1016/S0958-1669(03)00104-6 
 
Inde, Z., and Dixon, S. J. (2018). The impact of non-genetic heterogeneity on cancer cell death. 
Crit. Rev. Biochem. Mol. Biol. 53: 99-114. doi: 10.1080/10409238.2017.1412395 
 
Jusiak, B., Cleto, S., Perez-Piñera, P., and Lu, T. K. (2016). Engineering synthetic gene circuits 
is living cells with CRISPR technology. Trends Biotechnol. 34: 353-547. doi: 
10.1016/j.tibtech.2015.12.014 
 
Kolaczkowski, M., Kolaczoska, A., Luczynski, J., Witek, S., and Goffeau, A. (1998). In Vivo 
characterization of the drug resistance profile of the major ABC transporters and other 
components of the yeast pleiotropic drug resistance network. Microb. Drug. Resist. 4: 143-158. 
doi: 10.1089/mdr.1998.4.143 
 
Kussell, E., Kishony, R., Balaban, N. Q., and Leibler, S. (2005). Bacterial Persistence: A Model 
of Survival in Changing Environments. Genetics 169: 1807-1814. doi: 
10.1534/genetics.104.035352 
 
Langevin, A. M., and Dunlop, M. J. (2018). Stress introduction rate alters the benefit of AcrAB-
TolC efflux pumps. J. Bacteriol. 200: e00525-17. doi: 10.1128/JB.00525-17 
 
Lavi, O., Gottesman, M. M., and Levy, D. (2012). The dynamics of drug resistance: A 
mathematical perspective. Drug Resist. Updat. 15: 90-97. doi: 10.1016/j.drup.2012.01.003 
 
Levin-Reisman, I., Ronin, I., Gefen, O., Braniss, I, Shoresh, N., and Balaban, N. Q. (2017). 
Antibiotic tolerance facilitates the evolution of resistance. Science 355: 826-830. doi: 
10.1126/science.aaj2191 
 
Misra, S., Ghatak, S., and Toole, B. P. (2005). Regulation of MDR1 Expression and Drug 
Resistance by a Positive Feedback Loop Involving Hyaluronan, Phosphoinositide 3-Kinase, and 
ErbB2. J. Biol. Chem. 280: 20310-20315. doi: 10.1074/jbc.M500737200 
 
Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., et al. (1999). 
Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob. 
Agents Chemother. 43, 1856-1861. doi: 10.1128/AAC.43.8.1856 
 
Nevozhay, D., Adams, R. M., Itallie, E. V., Bennett, M. R., and Balázsi, G. (2012). Mapping the 
environmental fitness landscape of a synthetic gene circuit. PLoS Comput. Biol. 8: 1-17. doi: 
10.1371/journal.pcbi.1002480 
 
Nevozhay, D., Zal, T., and Balázsi, G. (2013). Transferring a synthetic gene circuit from yeast to 
mammalian cells. Nat. Commun. 4: 1-11. doi: 10.1038/ncomms2471 
 
Nissim, L., Perli, S. D., Fridkin, A., Perez-Pinera, P., and Lu, T. K. (2014). Multiplexed and 
programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in 
human cells. Mol. Cell. 54: 698-710. doi: 10.1016/j.molcel.2014.04.022 
 
Ochman, H., Lawrence, J. G., and Groisman, E. A. (2000). Lateral gene transfer and the nature 
of bacterial innovation. Nature 405: 299-304. doi: 10.1038/35012500 
 
O’Neill, J., and The Review on Antimicrobial Resistance (2016). Tackling Drug-Resistant 
Infections Globally: Final Report and Recommendations. Available at: http://amr-
review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf 
 
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., et al. (2018). Antifungal 
tolerance is a subpopulation effect distinct from resistance and is associated with persistent 
candidemia. Nat. Commun. 9: 2470. doi: 10.1038/s41467-018-04926-x 
 
Sakurai, Y., and Hori, Y. (2018). Optimization-based synthesis of stochastic biocircuits with 
statistical specifications. J. R. Soc. Interface 15: 20170709. doi: 10.1098/rsif.2017.0709 
Salgia, R., and Kulkarni, P. (2018). The genetic/non-genetic duality of drug ‘resistance’ in 
cancer. Trends Cancer 4: 110-118. doi: 10.1016/j.trecan.2018.01.001 
 
Santos-Moreno, J., and Schaerli, Y. (2019) A framework for the modular and combinatorial 
assembly of synthetic gene circuits. ACS Synth. Biol. 8: 1691-1697. doi: 
10.1021/acssynbio.9b00174 
 
Sears, D., and Schwartz, B. S. (2017). Candida Auris: an emerging multidrug-resistant pathogen. 
Int. J. Infect. Dis. 63: 95-98. doi: 10.1016/j.ijid.2017.08.017 
 
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., et al. (2017). 
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. 
Nature 546: 431-435. doi: 10.1038/nature22794 
 
van Boxtel, C., van Heerden, J. H., Nordholt, N., Schmidt, P., and Bruggeman, F. J. (2017). 
Taking chances and making mistakes: non-genetic phenotypic heterogeneity and its 
consequences for surviving in dynamic environments. J. R. Soc. Interface 14: 20170141. 
doi: 10.1098/rsif.2017.0141 
 
Vasan, N., Baselga, J., and Hyman, D. M. (2019). A view on drug resistance in cancer. Nature 
575: 299-309. doi: 10.1038/s41586-019-1730-1 
 
Wirth, D., and Hauser, H. (2004). Flp-mediated integration of expression cassettes into FRT-
tagged chromosomal loci in mammalian cells. Methods Mol. Biol. 267: 467-476. doi:10.1385/1-
59259-774-2:467 
 
Wuyts, J., Van Dijck, P., and Holtappels, M. (2018). Fungal persister cells: the basis for 
recalcitrant infections? PLoS Pathog. 14: e1007301. doi: 10.1371/journal.ppat.1007301 
 
World Health Organization (2014). Antimicrobial Resistance: Global report of surveillance. 
Available at:  https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf 
 
Zhang, Y., Yew, W. W., and Barer, M. R. (2012). Targeting persisters for tuberculosis control. 
Antimicrob. Agents Chemother. 56: 2223-2230. doi: 10.1128/AAC.06288-11. 
 
Zhuravel, D., Fraser, D., St-Pierre, S., Tepliakova, L., Pang, W. L., Hasty, J., et al. (2010). 
Phenotypic impact of regulatory noise in cellular stress-response pathways. Syst. Synth. Biol. 4: 
105-116. doi: 10.1007/s11693-010-9055-2 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic depicting the development of non-genetic and genetic drug resistance. (A) The 
development of genetic drug resistance via evolution by natural selection of a drug resistance mutation. 
(B) The development of non-genetic drug resistance in a clonal cell population via the selection cells with 
sufficiently long gene expression fluctuation timescales. The shade of green denotes the level of gene 
expression of a drug resistance gene inside the cell; lighter and darker shades of green represent lower 
levels and higher levels of gene expression, respectively. Inset illustrates gene expression histograms 
typically obtained from clonal cell populations with low and high levels of non-genetic, cell-to-cell 
variability. A high level of non-genetic variability is advantageous at high drug concentrations and a low 
level of non-genetic variability is advantageous at low drug concentrations (cells with resistance gene 
expression levels below a given drug threshold perish). (C) The evolution of longer-term, genetic drug 
resistance is facilitated by shorter-term, non-genetic drug resistance; the ultimate outcome will be 
determined based on the condition-dependent relative fitness of each subpopulation.  
 
 
 
 
 
Figure 2. Synthetic gene networks engineered to mimic natural drug resistance gene networks 
and study the effects of non-genetic heterogeneity on AMR. (A) Yeast pleiotropic drug 
resistance (PDR) gene network. Imbedded in this gene network structure are positive feedback 
regulation (self-activation of PDR3), negative feedback regulation (efflux of gene network-
inducing drug by PDR5), and feedforward regulation (PDR1 indirectly activates PDR5 through 
PDR3) and direct activation (PDR1 activates PDR5). (B) A synthetic gene network engineered to 
have the same network motif as the PDR network shown in (A). Note that fluorescence reporter 
genes, such as yEGFP, are fused to drug resistance genes, such as PDR5, to enable experimental 
measurement. (C) Schematic of the mammalian negative feedback (mNF) gene network, which 
expresses the humanized tetracycline repressor (hTetR) gene, the puromycin resistance gene 
(PuroR), and the fluorescence reporter EGFP separated by self-cleaving 2A elements. (D) 
Schematic of the mammalian positive feedback (mPF) gene network, which expresses the 
reverse tetracycline transactivator (rtTA), PuroR, and EGFP separated by self-cleaving 2A 
elements. (E) Schematic of representative gene expression histograms obtained from a dose 
response of the mNF strain. (F) Decoupled noise regime which occurs when the mean gene 
expression noise amplitude for the mPF (high noise) and the mNF (low noise) gene networks is 
decoupled from mean gene expression. (G) Schematic of representative gene expression 
histograms obtained from a dose response of the mPF strain. Legends in (E) and (G) indicate the 
inducer (doxycycline) level for each distribution. Panel (A) was reproduced from Charlebois et 
al., 2014 with permission (https://doi.org/10.1103/PhysRevE.89.052708), panel (B) was adapted 
with permission from Camellato, 2018, and panels (C) to (G) were adapted from Farquhar et al., 
2019, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). 
